Some parts of the portal may cause error messages or display incorrectly due to the transition to a new provider of trading data

IFRX - InflaRx N.V.


IEX Last Trade
1.6
-0.060   -3.750%

Share volume: 44,548
Last Updated: Fri 30 Aug 2024 09:59:48 PM CEST
Research and Development in Biotechnology (except Nanobiotechnology): 0.21%

PREVIOUS CLOSE
CHG
CHG%

$1.66
-0.06
-3.61%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Fundamental analysis
21%
Profitability 25%
Dept financing 5%
Liquidity 50%
Performance 15%
Company vs Stock growth
vs
Performance
5 Days
0.63%
1 Month
2.58%
3 Months
11.19%
6 Months
-8.62%
1 Year
-61.31%
2 Year
-29.65%
Key data
Stock price
$1.60
P/E Ratio 
0.00
DAY RANGE
$1.55 - N/A
EPS 
$0.00
52 WEEK RANGE
$1.14 - $4.30
52 WEEK CHANGE
-$0.62
MARKET CAP 
93.624 M
YIELD 
N/A
SHARES OUTSTANDING 
58.883 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
10/30/2024
BETA 
0.39
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$72,804
AVERAGE 30 VOLUME 
$63,174
Company detail
CEO:
Region: US
Website: https://www.inflarx.de/
Employees: 21
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services

inflarx n.v., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using c5a technology primarily in the germany and united states. its c5a is an inflammatory mediator that is involved in the enhancement of a variety of autoimmune and other inflammatory diseases. the company's lead product candidate is ifx-1, an intravenously delivered first-in-class anti-c5a monoclonal antibody, which completed the phase iib clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; to treat anca-associated vasculitis, a rare and life-threatening autoimmune disease; and for the treatment of pyoderma gangrenosum, a chronic inflammatory skin disorder, as well as developing ifx-1 for the treatment of oncological diseases. it also develops ifx-2 that is in pre-clinical development stage for the treatment of chronic inflammation and autoimmune diseases. inflarx n.v. has co-development agreement with beijing defe

Recent news